Please login to the form below

Not currently logged in
Email:
Password:

vinflunine

This page shows the latest vinflunine news and features for those working in and with pharma, biotech and healthcare.

Keytruda, Opdivo narrow Tecentriq's lead in bladder cancer

Keytruda, Opdivo narrow Tecentriq's lead in bladder cancer

The trial compared Keytruda to the investigator's choice of chemotherapy agents - paclitaxel, docetaxel or vinflunine - and showed that Merck's drug improved both progression-free survival (PFS) and overall survival.

Latest news

  • BMS abandons Pierre Fabre bladder cancer drug

    BMS and Pierre Fabre Medicament terminate their license agreement for the development of metastatic bladder cancer chemotherapy agent, vinflunine. ... US-based Bristol-Myers Squibb and France-headquartered Pierre Fabre Medicament have terminated their

  • Sanofi-aventis and BMS move closer toward merger

    BMS' oncology portfolio is also set to expand, with three oncology drug launches over the next two years: BMS 247550 (ixabepilone), MDX-010 (ipilimumab) and Javlor (vinflunine).

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics